Feature | Stents | July 31, 2015

Trio of Drug-Eluting Stents Driving European Interventional Cardiology Market

Abbott Laboratories, Boston Scientific and Medtronic offsetting 10 percent overall decline in 2014

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

July 31, 2015 — According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.

In 2014, the European markets for interventional cardiology were valued at nearly EUR 1.3 billion, a nearly 10 percent decrease from the previous year. The total European market for interventional cardiology devices is projected to decline as a result of continued decrease in average selling prices due to:

The competitive tender systems being adopted across Europe;
Low procedure numbers; and
A decrease in devices used per procedure due to improvements in medical devices and cardiologist best practices.


"Unit sales growth is expected to be driven by a new generation of drug-eluting stents, which are expected to alleviate physician concerns over thrombosis issues, as well as decreased ASPs which may trigger physicians to stent more," explained Kamran Zamanian, Ph.D., CEO of iData.

The negative growth experienced throughout many countries over 2011 and 2012 was due primarily to turbulent macroeconomic conditions throughout the European region. The United Kingdom showed the largest decline due to the entrance of substantially lower priced products being brought into the country from Germany. Benelux and Spain are also expected to see large market declines due to prevalent price erosion and the lackluster unit sales growth in their respective markets. Spending cuts throughout many countries and uncertainty regarding default were major contributors to the stifling of growth of many markets. Austria is expected to be the only country to experience growth due to its premium pricing system modeled after the Swiss market and its proximity to the leading German market.

Abbott Laboratories has been the leading competitor in the drug-eluting stent (DES) market with more than 30 percent market share. Their actual selling price for DES has been quite low due to competition with Boston Scientific. Other competitors include Medtronic, Biotronik, B. Braun, Biosensors International, Cornova and Disa Vascular, among others.

For more information: www.idataresearch.com

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init